Pfizer booster shows promise in kids' trial

A booster shot of the coronavirus vaccine made by Pfizer-BioNTech increased the level of neutralizing antibodies against both the original version of the virus and the omicron variant in a small trial of children age 5 to 11, the companies announced Thursday.

Related Keywords

New York ,United States ,Boston ,Massachusetts ,Washington ,Americans ,Carolyny Johnson ,Lauran Neergaard ,Philip Krause ,Kathrynm Edwards ,Sharon Lafraniere ,Centers For Disease ,Pfizer ,New York Times ,Washington Post ,Vanderbilt University School Of Medicine ,Drug Administration ,Associated Press ,Disease Control ,Vanderbilt University School ,Ofer Levy ,Boston Children ,